Abstract:Background: Homozygous familial hypercholesterolemia (HoFH) is an orphan metabolic disease characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C), xanthomas, aortic stenosis, and premature atherosclerotic cardiovascular disease (ASCVD). In addition to LDL-C, studies in experimental models and small clinical populations have suggested that other types of metabolic molecules might also be risk factors responsible for cardiovascular complications in HoFH, but definitive evidence from large-scale human studies is still lacking. Herein, we aimed to comprehensively characterize the metabolic features and risk factors of human HoFH by using metabolic systems strategies. Methods: Two independent multi-center cohorts with a total of 868 individuals were included in the cross-sectional study. First, comprehensive serum metabolome/lipidome-wide analyses were employed to identify the metabolomic patterns for differentiating HoFH patients (n = 184) from heterozygous FH (HeFH, n = 376) and non-FH (n = 100) subjects in the discovery cohort. Then, the metabolomic patterns were verified in the validation cohort with 48 HoFH patients, 110 HeFH patients, and 50 non-FH individuals. Subsequently, correlation/regression analyses were performed to investigate the associations of clinical/metabolic alterations with typical phenotypes of HoFH. In the prospective study, a total of 84 HoFH patients with available follow-up were enrolled from the discovery cohort. Targeted metabolomics, deep proteomics, and random forest approaches were performed to investigate the ASCVD-associated biomarkers in HoFH patients. Results: Beyond LDL-C, various bioactive metabolites in multiple pathways were discovered and validated for differentiating HoFH from HoFH and non-FH. Our results demonstrated that the inflammation and oxidative stress-related metabolites in the pathways of arachidonic acid and lipoprotein(a) metabolism were independently associated with the prevalence of corneal arcus, xanthomas, and supravalvular/valvular aortic stenosis in HoFH patients. Our results also identified a small marker panel consisting of high-density lipoprotein cholesterol, lipoprotein(a), apolipoprotein A1, and eight proinflammatory and proatherogenic metabolites in the pathways of arachidonic acid, phospholipid, carnitine, and sphingolipid metabolism that exhibited significant performances on predicting first ASCVD events in HoFH patients. Conclusions: Our findings demonstrate that human HoFH is associated with a variety of metabolic abnormalities and is more complex than previously known. Furthermore, this study provides additional metabolic alterations that hold promise as residual risk factors in HoFH population.

New Insights into the Underlying Mechanisms

Metabolically healthy obesity in adults with X-linked hypophosphatemia

Clinical and Genetic Characteristics of 153 Chinese Patients with X-Linked Hypophosphatemia

X-Linked hypophosphatemia. Data from a Spanish adult population cohort

FGF23 and its role in X-linked hypophosphatemia-related morbidity

Clinical and Genetic Analysis in a Large Chinese Cohort of Patients with X-linked Hypophosphatemia

Abstract P281: Urinary Metabolites Associated With Blood Pressure on a Low- or High-sodium Diet

X-Linked Hypophosphatemia, Not Only a Skeletal Disease But Also a Chronic Inflammatory State

Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: Results From a Sponsored Genetic Testing Program

Nephrocalcinosis and Kidney Function in Children and Adults with X-linked Hypophosphatemia: Baseline Results from a Large Longitudinal Study

Urinary Metabolites Associated With Blood Pressure On A Low- Or High-Sodium Diet.

Cross-Sectional Blood Metabolite Markers of Hypertension: A Multicohort Analysis of 44,306 Individuals from the COnsortium of METabolomics Studies

Hyperparathyroidism in Patients With X-Linked Hypophosphatemia

A pilot study to identify the longitudinal serum metabolite profiles to predict the development of hyperuricemia in essential hypertension

Clinical and Molecular Perspectives of Monogenic Hypertension

FGF23, Hypophosphatemia, and Emerging Treatments

Gut metagenomic and short chain fatty acids signature in hypertension: a cross-sectional study

The Gene Polymorphism of LOX1 Predicts the Incidence of LVH in Patients with Essential Hypertension

Unique intestinal microflora and metabolic profile in different stages of hypertension reveal potential biomarkers for early diagnosis and prognosis

Altered adolescents obesity metabolism is associated with hypertension: a UPLC-MS-based untargeted metabolomics study

Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia